Try our Advanced Search for more refined results

FEDERAL TRADE COMMISSION v. CEPHALON, INC.

  1. October 13, 2021

    Louisiana Can't Wade Into FTC's Settled Provigil Case

    A Pennsylvania federal court on Wednesday rejected a bid from the state of Louisiana to intervene in a case over the alleged delay of generic versions of narcolepsy drug Provigil that the Federal Trade Commission settled with Teva through a $1.2 billion deal in 2015.

  2. October 29, 2019

    ​​​​​​​Allergan's $750M Deal Among Pharma's Top Antitrust Payouts

    A $750 million settlement this week by Allergan to avert an antitrust trial involving Alzheimer's drug Namenda is among the most eye-popping sums ever shelled out by a drugmaker for allegedly thwarting generic competition.

  3. February 20, 2019

    FTC's Teva Settlement A Sign Of Enforcement Evolution

    The Federal Trade Commission's settlement this week with Teva Pharmaceuticals further winnows the types of deals the company can sign with would-be competitors and illuminates the agency's evolving approach to cases in which drug companies are accused of colluding to delay competition.

  4. June 17, 2015

    Judge OKs $1.2B Cephalon Deal In FTC Pay-For-Delay Suit

    A Pennsylvania federal judge on Wednesday approved the Federal Trade Commission's record-setting $1.2 billion settlement with Cephalon Inc. in a long-running antitrust suit accusing the company of paying generic-drug makers to hold off on launching their own version of narcolepsy treatment Provigil.

  5. May 28, 2015

    Pay-For-Delay Questions Linger After $1.2B Cephalon Deal

    The Federal Trade Commission's record-setting $1.2 billion settlement with Cephalon Inc. on Thursday gives the antitrust watchdog a boost as it continues to challenge so-called pay-for-delay settlements. But the eleventh-hour deal disappointed observers who had hoped for answers to lingering questions about how to prosecute the complex cases.

  6. May 28, 2015

    FTC's $1.2B Win Shows Pay-For-Delay Deals On Thin Ice

    The Federal Trade Commission's $1.2 billion settlement with Cephalon Inc. over the company's huge payments to rivals is a fresh sign that so-called pay-for-delay deals involving big exchanges of money will be difficult to defend in the wake of a landmark U.S. Supreme Court decision from two years ago, experts say.

  7. May 28, 2015

    Paying The Price For Pay-For-Delay: Cephalon's 7-Year Saga

    With a $1.2 billion settlement on Thursday ending the Federal Trade Commission’s long-running case against Cephalon Inc. for allegedly paying rivals to hold off selling generic versions of the narcolepsy drug Provigil, Law360 takes a look back at the seven-year antitrust fight.

  8. May 28, 2015

    FTC Health Care Chief: $1.2B Cephalon Deal A Strong Warning

    Cephalon Inc.'s promise to settle patent litigation without using side deals to get reverse payments as part of a $1.2 billion agreement with the Federal Trade Commission sends a "strong and important" message to the rest of the industry to change its behavior, FTC health care chief Markus Meier told Law360 on Thursday.

  9. May 28, 2015

    Cephalon To Pay $1.2B To End FTC Pay-For-Delay Suit

    Cephalon Inc. agreed Thursday to pay $1.2 billion to settle a long-running antitrust suit accusing the company of paying generic-drug makers to hold off on launching their own version of narcolepsy treatment Provigil, handing the Federal Trade Commission a major victory in its decadelong campaign against so-called pay-for-delay patent settlements.

  10. April 16, 2015

    FTC Can Seek Disgorgement In Cephalon Suit, Judge Says

    The Federal Trade Commission can pursue billions of dollars Cephalon Inc. allegedly made through a series of pay-for-delay deals meant to stave off competition with its blockbuster narcolepsy drug, a Pennsylvania federal judge ruled Wednesday.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!